Influence of β-lactam pharmacodynamics on the systems microbiology of gram-positive and gram-negative polymicrobial communities
Nicholas M. Smith, Harpreet Kaur, Ravneet Kaur, Trisha Minoza, Michael Kent, Ayeh Barekat, Justin R. Lenhard

TL;DR
This study shows how β-lactamase-producing E. coli can protect other bacteria from β-lactam antibiotics in mixed infections.
Contribution
The study introduces a systems microbiology approach to quantify β-lactam antibiotic interactions in polymicrobial communities.
Findings
β-lactamase-producing E. coli reduced the effectiveness of ampicillin and cefazolin against co-cultured gram-positive bacteria.
Mathematical models revealed that E. coli protected S. aureus and E. faecalis by reducing antibiotic potency parameters like Kmax.
The presence of β-lactamase-producing E. coli significantly lowered the maximum killing (Emax) of β-lactam antibiotics.
Abstract
We sought to evaluate the pharmacodynamics of β-lactam antibacterials against polymicrobial communities of clinically relevant gram-positive and gram-negative pathogens. Two Enterococcus faecalis isolates, two Staphylococcus aureus isolates, and three Escherichia coli isolates with varying β-lactamase production were evaluated in static time-killing experiments. Each gram-positive isolate was exposed to a concentration array of ampicillin (E. faecalis) or cefazolin (S. aureus) alone and during co-culture with an E. coli isolate that was β-lactamase-deficient, produced TEM-1, or produced KPC-3/TEM-1B. The results of the time-killing experiments were summarized using an integrated pharmacokinetic/pharmacodynamics analysis as well as mathematical modelling to fully characterize the antibacterial pharmacodynamics. In the integrated analysis, the maximum killing of ampicillin (Emax)…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAntibiotics Pharmacokinetics and Efficacy · Antibiotic Resistance in Bacteria · Antibiotic Use and Resistance
